Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
30 Jun 2020

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020

Maintenance treatment in multiple myeloma: A new era

Prof Sagar Lonial and Prof Wee-Joo Chng
Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )
18 Jun 2020

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
17 Jun 2020

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada
Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )
16 Jun 2020

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
15 Jun 2020

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020